Rethinking the benefits and costs of childhood vaccination: The example of the Haemophilus influenzae type b vaccine

Baernighausen Till; Bloom David E. Author Reprint Author; E-mail: dbloom@hsph.harvard.edu; Canning David Author; E-mail: dcanning@hsph.harvard.edu; Friedman Abigail Author; E-mail: afriedm@fas.harvard.edu; Levine Orin S. Author; E-mail: olevine@jhsph.edu; OBrien Jennifer Author; E-mail: jobrien@hsph.harvard.edu; Privor-Dumm Lois Author; E-mail: lprivord@jhsph.edu; Walker Damian Author; E-mail: Damian.Walker@gatesfoundation.org.

首页> 外文期刊>Vaccine >Rethinking the benefits and costs of childhood vaccination: The example of the Haemophilus influenzae type b vaccine

【24h】

Rethinking the benefits and costs of childhood vaccination: The example of the Haemophilus influenzae type b vaccine

机译：重新思考儿童接种疫苗的收益和成本：以B型流感嗜血杆菌疫苗为例

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Economic evaluations of health interventions, such as vaccinations, are important tools for informing health policy. Approaching the analysis from the appropriate perspective is critical to ensuring the validity of evaluation results for particular policy decisions. Using the example of cost-benefit analysis (CBA) of Haemophilus influenzae type b (Hib) vaccination, we demonstrate that past economic evaluations have mostly adopted narrow evaluation perspectives, focusing primarily on health gains, health-care cost savings, and reductions in the time costs of caring, while usually ignoring other important benefits including outcome-related productivity gains (improved economic productivity due to prevention of mental and physical disabilities), behavior-related productivity gains (economic growth due to fertility reductions as vaccination improves child survival), and community externalities (herd immunity and prevention of antibiotic resistance). We further show that potential cost reductions that could be attained through changes in the delivery of the Hib vaccine have also generally been ignored in economic evaluations. Future economic evaluations of childhood vaccinations should take full account of benefits and costs, so that policymakers have sufficient information to make well-informed decisions on vaccination implementation

机译：对卫生干预措施（例如疫苗）的经济评估是告知卫生政策的重要工具。从适当的角度进行分析对于确保特定政策决策的评估结果的有效性至关重要。以乙型流感嗜血杆菌（Hib）疫苗的成本效益分析（CBA）为例，我们证明了过去的经济评估大多采用了狭窄的评估视角，主要侧重于健康收益，医疗保健成本的节省以及对医疗费用的减少。照护的时间成本，而通常忽略了其他重要的好处，包括与结果相关的生产力提高（由于预防精神和身体残疾而提高了经济生产力），与行为相关的生产力提高（由于疫苗接种提高了儿童存活率而导致的生育力降低）所带来的经济增长，和社区外部性（畜群免疫力和对抗生素耐药性的预防）。我们进一步表明，通过改变Hib疫苗的输送量可以实现的潜在成本降低在经济评估中通常也被忽略。对儿童疫苗的未来经济评估应充分考虑收益和成本，以便政策制定者有足够的信息来就疫苗接种的实施做出明智的决定

著录项

来源
《Vaccine》 |2011年第13期|共10页
作者
Baernighausen Till; Bloom David E. Author Reprint Author; E-mail: dbloom@hsph.harvard.edu; Canning David Author; E-mail: dcanning@hsph.harvard.edu; Friedman Abigail Author; E-mail: afriedm@fas.harvard.edu; Levine Orin S. Author; E-mail: olevine@jhsph.edu; OBrien Jennifer Author; E-mail: jobrien@hsph.harvard.edu; Privor-Dumm Lois Author; E-mail: lprivord@jhsph.edu; Walker Damian Author; E-mail: Damian.Walker@gatesfoundation.org.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
Haemophilus influenzae type b vaccine: Hib vaccine; immunologic-drug; antiviral-drug; antiinfective-; antibiotic resistance; economic evaluation; health policy; herd immunity; economic productivity; child survival; health intervention; health gain; health-care cost saving; behavior-related productivity gain;

机译：乙型流感嗜血杆菌疫苗：Hib疫苗;免疫药;抗病毒药;抗感染药;抗生素耐药性;经济评估;卫生政策;畜群免疫力;经济生产力;儿童生存;健康干预;健康收益;卫生保健成本节省;与行为有关的生产率提高;

相似文献

外文文献
中文文献
专利

1. Rethinking the benefits and costs of childhood vaccination: The example of the Haemophilus influenzae type b vaccine [J] . Baernighausen Till, Bloom David E. Author Reprint Author, E-mail: dbloom@hsph.harvard.edu, Vaccine . 2011,第13期

机译：重新思考儿童接种疫苗的收益和成本：以B型流感嗜血杆菌疫苗为例
2. A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand [J] . Lijoy Varghese, Louise Talbot, Andrea Govender, Applied health economics and health policy . 2018,第3期

机译：与新西兰通用大规模疫苗接种实施的13价肺炎球菌缀合物疫苗（PCV13）相比，10价肺炎球菌非典型血液植物甲型蛋白D缀合物（PHID-CV）的成本效益分析
3. Budget impact analysis of vaccination against Haemophilus influenzae type b as a part of a Pentavalent vaccine in the childhood immunization schedule of Iran [J] . Fatemeh Teimouri, Abbas Kebriaeezadeh, Seyed Mohsen Zahraei, Daru Journal of pharmaceutical sciences. . 2017,第1期

机译：伊朗儿童期免疫计划中作为五价疫苗一部分的乙型流感嗜血杆菌疫苗接种的预算影响分析
4. Wastage of Diphtheria, Tetanus, Pertussis and Haemophilus influenzae type-b vaccine (Tetravalent vaccine) and its impact on the increase of dose costs [C] . Novaes M. L. O., Almeida R. M. V., Bastos R. R., Pan American Health Care Exchanges Conference . 2011

机译：白喉，破伤风，百日咳和流感嗜血杆菌b型疫苗（四价疫苗）的浪费及其对剂量费用增加的影响
5. Protein Vaccines Against Acute Otitis Media Caused by Nontypeable Haemophilus influenzae in a Murine Model [D] . Zavorin, Mark. 2018

机译：蛋白质疫苗针对鼠模型中的不可迁移血液血液嗜血杆菌引起的急性中耳炎
6. A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand [O] . Lijoy Varghese, Louise Talbot, Andrea Govender, -1

机译：在新西兰实施10价肺炎球菌不可分型流感嗜血杆菌D蛋白共轭疫苗（PHiD-CV）与13价肺炎球菌共轭疫苗（PCV13）的成本效益分析
7. Rethinking the benefits and costs of childhood vaccination: the example of the Haemophilus influenzae type b vaccine [O] . Till BÃ¤rnighausen, David E. Bloom, David Canning, 100

机译：重新思考儿童疫苗接种的益处和成本：b型流感嗜血杆菌疫苗的例子

Rethinking the benefits and costs of childhood vaccination: The example of the Haemophilus influenzae type b vaccine

摘要

著录项

相似文献

相关主题

期刊订阅